# SPI-1005 for the Treatment of Patients With Meniere's Disease

> **NCT03325790** · PHASE2 · COMPLETED · sponsor: **Sound Pharmaceuticals, Incorporated** · enrollment: 149 (actual)

## Conditions studied

- Meniere's Disease

## Interventions

- **DRUG:** 200mg SPI-1005 BID
- **DRUG:** 400mg SPI-1005 BID
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03325790
- **Lead sponsor:** Sound Pharmaceuticals, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-28
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-04-30
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325790, "SPI-1005 for the Treatment of Patients With Meniere's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03325790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*